Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lexaria Bioscience Corp (NQ: LEXX )

3.090 +0.090 (+3.00%)
Streaming Delayed Price Updated: 12:06 PM EDT, May 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Lexaria Bioscience Corp

< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Pivotal Milestones Concerning DehydraTECH(TM) Technology, Including IND Application Plans
Via Investor Brand Network
TinyGemsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Study Demonstrates Significant Enhancement in Oral Estradiol Delivery
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Lexaria's Hormone Study Shows Significant Enhancement in Oral Estradiol Delivery
Via ACCESSWIRE
Lexaria Bioscience Corp. (NASDAQ: LEXX) Kicks Off FDA IND Filing Process with Granted CRO Contract to California-Based InClin, Inc.
Via Investor Brand Network
Exposures Product Safety
Lexaria Announces 2023 Annual Meeting Results
Via ACCESSWIRE
Lexaria Awards CRO Contract for Upcoming U.S. Phase 1b Hypertension Study
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Secures $2M in Public Offering
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Secures $2M in Public Offering
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Completion of cGMP Manufacturing for Upcoming Clinical Trial
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Completion of cGMP Manufacturing for Upcoming Clinical Trial
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Lexaria Bioscience Announces Closing of $2.0 Million Public Offering
Via ACCESSWIRE
cGMP Manufacturing Complete for Lexaria's Upcoming U.S. Phase 1b Hypertension Clinical Trial
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Results of 2023 Annual Meeting
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Results of 2023 Annual Meeting
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Bioscience Announces Pricing of $2.0 Million Public Offering
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Dosing Completed on Human Clinical Nicotine Study
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Dosing Completed on Human Clinical Nicotine Study
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Four New Patents Added to the Company’s Growing Patent Portfolio
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Lexaria’s Human Clinical Nicotine Study Completes Dosing as Planned
Via ACCESSWIRE
Lexaria Bioscience Corp. (NASDAQ: LEXX), Featured in Recent Research Report by Zacks SCR
Via Investor Brand Network
Topics Bonds
Exposures Debt Markets
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Successful DIAB-A22-1 Diabetes Study Indicates Just One of Several Potential Applications for DehydraTECH(TM) Drug Delivery Platform Technology
Via Investor Brand Network
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Awards CRO Contract for Upcoming Hypertension Study
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Expanding Portfolio with Four New Patents
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Lexaria is Receiving Four New Patents
Via ACCESSWIRE
Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyes the Licensed Use of its DehydraTECH(TM) Technology to Complement its Royalty Earnings and Realize Revenue in Advance of Royalties
Via Investor Brand Network
TinyGemsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Demonstrates Positive Results in First Diabetes Study
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Revolutionizing Drug Delivery Potential for Active Pharmaceutical Ingredients Using Patented DehydraTECH(TM) Technology
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Targeting Multiple Commercial Applications for Its Patented DehydraTECH(TM) Technology Platform
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Provides Foundation for Improving Effectiveness of Lipophilic Drugs, APIs
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Provides Foundation for Improving Effectiveness of Lipophilic Drugs, APIs
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.